Edesa Biotech Inc (EDSA) Stock Analysis

AI analysis of Edesa Biotech Inc (EDSA)

Sell

Edesa Biotech Inc is not a good buy right now due to its extremely low RSI of 18.774, indicating oversold conditions, and a significant recent decline of 15.56% over the last five days. The stock is currently trading at $2.17, far below its 52-week high of $20.32, which suggests a lack of immediate upward momentum. Additionally, the company reported a net loss of $5.4 million for Q2 2026, which is a widening loss compared to previous quarters, raising concerns about its financial health. The main risk is its forward P/E ratio of 0.1785, indicating potential volatility and uncertainty in future earnings performance.

Valuation Metrics

The current forward P/E ratio for Edesa Biotech Inc (EDSA) is 0.18, compared to its 5-year average forward P/E of -1.78.

Forward P/E

Overvalued

5Y Average P/E

-1.78

Current P/E

0.18

Overvalued

-0.33

Undervalued

-3.24

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.05

Current EV/EBITDA

0.00

Overvalued

0.83

Undervalued

-0.73

Forward P/S

Fair

5Y Average P/S

2.54

Current P/S

0.00

Overvalued

8.88

Undervalued

-3.80

Alphio AI Price Scenarios for EDSA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EDSA

$3.51

Scenario price

B

Base

Base · 50%EDSA

$2.90

Scenario price

B

Bear

Bear · 25%EDSA

$2.36

Scenario price

EDSA FAQ — answered by Alphio AI

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Edesa Biotech Inc is not a good buy right now due to its extremely low RSI of 18.774, indicating oversold conditions, and a significant recent decline of 15.56% over the last five days. The stock is currently trading at $2.17, far below its 52-week high of $20.32, which suggests a lack of immediate upward momentum. Additionally, the company reported a net loss of $5.4 million for Q2 2026, which is a widening loss compared to previous quarters, raising concerns about its financial health. The main risk is its forward P/E ratio of 0.1785, indicating potential volatility and uncertainty in future earnings performance.